Evogene
EVGN
16 hedge funds and large institutions have $52.2M invested in Evogene in 2015 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 0 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
7% more funds holding
Funds holding: 15 → 16 (+1)
0% more capital invested
Capital invested by funds: $52M → $52.2M (+$213K)
0.11% more ownership
Funds ownership: 2.23% → 2.34% (+0.11%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.89M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$693K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$97.9K |
| 4 |
MCM
Moon Capital Management
New York
|
+$9.13K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$559 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$39.1K |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$35.9K |
| 3 |
Citigroup
New York
|
-$3.45K |
EVGN Hedge Fund Activity: Q1 2015 in Review
16 of the 3,754 institutional investors tracked by Wall St. Rank reported a position in Evogene (EVGN) for Q1 2015, worth a combined $52.2M — up 0.41% from $52M a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new EVGN positions and 0 closed out — a net gain of 1 holder — while 4 added to existing stakes and 3 trimmed.
The largest buyer was Vanguard Group, opening a new position worth an estimated $1.89M. The largest seller was JP Morgan Chase, cutting an estimated $39.1K.
- 16 institutional investors held Evogene (EVGN) as of Q1 2015, up from 15 in Q4 2014.
- Funds reported $52.2M of Evogene stock for Q1 2015, up 0.41% quarter-over-quarter.
- 1 fund opened new Evogene positions in Q1 2015 and 0 closed out, a net change of +1 holder.
- The largest Evogene buyer in Q1 2015 was Vanguard Group, an estimated $1.89M added.
- The largest Evogene seller in Q1 2015 was JP Morgan Chase, an estimated $39.1K sold.
Based on aggregated 13F filings for Q1 2015.